Celecoxib as Adjunctive Therapy for Treatment of Colorectal Cancer

North, Ginnie Lee T.

doi:10.1345/aph.10133

Cited by 29 publications

(17 citation statements)

References 13 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early clinical studies involving patients with FAP demonstrated that celecoxib, a specific COX-2 inhibitor, induced significant regression of existing adenomas (39). These findings led to the accelerated FDA approval of celecoxib for adjuvant therapy in the treatment of familial adenomatous polyposis in 1999 (42). Studies have also indicated that celecoxib may have activity against other cancers, such as ovarian cancer, as well (43).…”

Section: Current Status Of Anti-inflammatory Agents For Cancermentioning

confidence: 99%

Anti-Inflammatory Agents for Cancer Therapy

Rayburn

Ezell²,

Zhang³

2009

Mol Cell Pharmacol

295

219

View full text Add to dashboard Cite

Inflammation is closely linked to cancer, and many anti-cancer agents are also used to treat inflammatory diseases, such as rheumatoid arthritis. Moreover, chronic inflammation increases the risk for various cancers, indicating that eliminating inflammation may represent a valid strategy for cancer prevention and therapy. This article explores the relationship between inflammation and cancer with an emphasis on epidemiological evidence, summarizes the current use of anti-inflammatory agents for cancer prevention and therapy, and describes the mechanisms underlying the anti-cancer effects of anti-inflammatory agents. Since monotherapy is generally insufficient for treating cancer, the combined use of anti-inflammatory agents and conventional cancer therapy is also a focal point in discussion. In addition, we also briefly describe future directions that should be explored for anti-cancer anti-inflammatory agents.

show abstract

Section: Current Status Of Anti-inflammatory Agents For Cancermentioning

confidence: 99%

Anti-Inflammatory Agents for Cancer Therapy

Rayburn

Ezell²,

Zhang³

2009

Mol Cell Pharmacol

295

219

View full text Add to dashboard Cite

show abstract

“…Celecoxib (CELEBREX ® , Onseral ® , Pfizer, New York, USA), a selective COX-2 inhibitor, has been reported to inhibit the growth of human cancer cell lines (Bocca et al, 2011; Dhawan et al, 2010; Liu et al, 2009; North, 2001). There have been minimal reported data concerning the use of COX-2-specific inhibitors as potential antineoplastic drugs in canine malignant melanoma.…”

mentioning

confidence: 99%

Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines

Seo

Coh

Rebhun

et al. 2014

Research in Veterinary Science

View full text Add to dashboard Cite

Cyclooxygenase-2 (COX-2) is a potential target for chemoprevention and cancer therapy. Celecoxib, a selective COX-2 inhibitor, inhibits cell growth of various types of human cancer including malignant melanoma. In dogs, oral malignant melanoma represents the most common oral tumor and is often a fatal disease. Therefore, there is a desperate need to develop additional therapeutic strategies. The purpose of this study was to investigate the anticancer effects of celecoxib on canine malignant melanoma cell lines that express varying levels of COX-2. Celecoxib induced a significant anti-proliferative effect in both LMeC and CMeC-1 cells. In the CMeC cells, treatment of 50 µM celecoxib caused an increase in cells in the G0/G1 and a decreased proportion of cells in G-2 phase. In the LMeC cells, 50 µM of celecoxib led to an increase in the percentage of cells in the sub-G1 phase and a significant activation of caspase-3 when compared to CMeC-1 cells. In conclusion, these results demonstrate that celecoxib exhibits antitumor effects on canine melanoma LMeC and CMeC-1 cells by induction of G1-S cell cycle arrest and apoptosis. Our data suggest that celecoxib might be effective as a chemotherapeutic agent against canine malignant melanoma.

show abstract

“…COX-2 is critical for the development of colorectal neoplasia [16]. COX-2 inhibitors can reduce intestinal inflammation leading to tumorigenesis [17] and are therefore used to treat familial adenomatous polyposis (FAP) patients [18] and patients with colorectal cancer [19]. Accumulating evidence has shown that prostaglandin E 2 (PGE 2 ), the main product of cyclooxygenase-2 (COX-2) activity, can promote a number of molecular mechanisms involved in colorectal carcinogenesis [20] in particular tumor cell proliferation and angiogenesis [21–24].…”

Section: Introductionmentioning

confidence: 99%

Suppression of Tumorigenesis: Modulation of Inflammatory Cytokines by Oral Administration of Microencapsulated Probiotic Yogurt Formulation

Urbanska

Paul

Bhahena

et al. 2010

International Journal of Inflammation

View full text Add to dashboard Cite

The objective of this study was to examine the ability of a novel microencapsulated probiotic yogurt formulation to suppress the intestinal inflammation. We assessed its anticancer activity by screening interleukin-1, 6, and 12 (IL-1, 6, 12), secretory levels of tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), prostaglandin E2 (PGE2), and thromboxane B2 in the digesta obtained from the duodenum, jejunum, proximal, and distal segments of the ileum of C57BL/6J-ApcMin/J mice. Formulation-receiving animals showed consistently lower proinflammatory cytokines' levels when compared to control group animals receiving empty alginate-poly-L-lysine-alginate (APA) microcapsules suspended in saline. The concentrations of IL-12 found in serum in control and treatment group animals were significant: 46.58 ± 16.96 pg/mL and 158.58 ± 28.56 pg/mL for control and treatment animals, respectively. We determined a significant change in plasma C-reactive protein: 81.04 ± 23.73 ng/mL in control group and 64.21 ± 16.64 ng/mL in treatment group. Western blots showed a 71% downregulation of cyclooxygenase-2 (COX-2) protein in treatment group animals compared to control. These results point to the possibility of using this yogurt formulation in anticancer therapies, in addition to chronic gut diseases such as Crohn's disease, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD) thanks to its inflammation lowering properties.

show abstract

Celecoxib as Adjunctive Therapy for Treatment of Colorectal Cancer

Cited by 29 publications

References 13 publications

Anti-Inflammatory Agents for Cancer Therapy

Anti-Inflammatory Agents for Cancer Therapy

Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines

Suppression of Tumorigenesis: Modulation of Inflammatory Cytokines by Oral Administration of Microencapsulated Probiotic Yogurt Formulation

Contact Info

Product

Resources

About